Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Enrolling by invitation 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Melanoma 146Carcinoma, Non-Small-Cell Lung 112Carcinoma, Renal Cell 74Neoplasm Metastasis 53Carcinoma, Hepatocellular 51Squamous Cell Carcinoma of Head and Neck 50Lung Neoplasms 48Colorectal Neoplasms 34Pancreatic Neoplasms 30Neoplasms 30Hodgkin Disease 30Urinary Bladder Neoplasms 24Sarcoma 23Brain Neoplasms 23Stomach Neoplasms 22Head and Neck Neoplasms 21Breast Neoplasms 21Prostatic Neoplasms 20Carcinoma, Transitional Cell 20Glioblastoma 19Recurrence 17Colonic Neoplasms 17Kidney Neoplasms 16Uveal Melanoma 15Small Cell Lung Carcinoma 15Multiple Myeloma 15Esophageal Neoplasms 15Carcinoma, Squamous Cell 14Skin Neoplasms 13Leukemia, Myeloid, Acute 13

Interventions

Bevacizumab 2regramostim 1recombinant human tumor necrosis factor-binding protein-1 1pembrolizumab 1molgramostim 1irinotecan sucrosofate 1Nivolumab 1Immune Checkpoint Inhibitors 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Malignant Ascites × Nivolumab × Clear all
NCT05745233 2023-08-24

Intraperitoneal Immune Checkpoint Inhibitor for Malignant Ascites

China Medical University Hospital

Phase NA Enrolling by invitation
30 enrolled

Malignant Ascites

Data powered by HemOnc (CC BY 4.0) Colophon âš¡